Paclitaxel and Capecitabine for Advanced Gastric Cancer
Author Information
Author(s): Kang H J, Chang H M, Kim T W, Ryu M-H, Sohn H-J, Yook J H, Oh S T, Kim B S, Lee J-S, Kang Y-K
Primary Institution: University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
Hypothesis
The combination of paclitaxel and capecitabine will be effective as first-line therapy for advanced gastric cancer.
Conclusion
The combination of paclitaxel and capecitabine is effective and well tolerated as a first-line chemotherapy for advanced gastric cancer.
Supporting Evidence
- Overall response rate was 48.9% with 2 complete responses and 20 partial responses.
- Median time to progression was 5.6 months.
- Median overall survival was 11.3 months.
- 46.5% of patients experienced grade 3 or 4 neutropaenia.
Takeaway
Doctors tested two medicines, paclitaxel and capecitabine, to see if they could help people with a serious stomach cancer, and they found that many patients got better.
Methodology
Patients with advanced gastric cancer were treated with paclitaxel and capecitabine, and their responses were evaluated after a median of 6 cycles of treatment.
Potential Biases
Potential bias due to the single-arm design and lack of a control group.
Limitations
The study had a small sample size and was limited to patients with specific eligibility criteria.
Participant Demographics
Median age was 57 years, with 71.1% male and 28.9% female participants.
Statistical Information
P-Value
p=0.459
Confidence Interval
95% CI=30.3–63.5%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website